Current Guidelines on Antithrombotic Management in Patients Undergoing Gastrointestinal Endoscopy
Keywords:
Anticoagulant, Antiplatelet, Antithrombotic, Gastrointestinal endoscopyAbstract
Endoscopic procedure is commonly used to make diagnosis or therapy. Endoscopy has risk on the procedure or after the procedure. Patient with antithrombotic therapy, both antiplatelet and/or anticoagulant, for underlying diseases has higher risk for bleeding and thromboembolic events in this procedure. The physician should consider risk and benefit for adjusting the antithrombotic therapy, in addition to minimize bleeding and thromboembolic events. For low risk procedure, adjustments in antithrombotic therapy usually not necessarily needed. For high risk procedure, there are several adjustments based on the type of medication and patient’s condition in specific. European Society of Gastrointestinal Guidelines Endoscopy (ESGE) and British Society of Gastrointestinal (BSG); American Society of Gastrointestinal Endoscopy (ASGE); and lastly Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) have published guidelines to help physician to make decisions regarding antithrombotic therapy management during endoscopy. This article compares and contrasts the approach of each guideline, in design to help the decision-making process. However, each patient’s clinical condition may differ from one to another and should be considered carefully in making a final decision.References
Chan FKL, Goh K-L, Reddy N, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut. BMJ Publishing Group; 2018;67(3):405–17.
Acosta RD, Abraham NS, Chandrasekhara V, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. Elsevier, Inc.; 2016;83(1):3–16.
Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including Direct Oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal endoscopy (ESGE) guidelines. Gut. 2016;65(3):374–89.
Whitson MJ, Dikman AE, von Althann C, et al. Is gastroduodenal biopsy safe in patients receiving Aspirin and Clopidogrel? J Clin Gastroenterol. 2011;45(3):228–33.
Ono S, Fujishiro M, Kodashima S, et al. Evaluation of safety of endoscopic biopsy without cessation of antithrombotic agents in Japan. J Gastroenterol. 2012;47(7):770–4.
Fujita M, Shiotani A, Murao T, et al. Safety of gastrointestinal endoscopic biopsy in patients taking antithrombotics. Dig Endosc. 2015;27(1):25–9.
Yuki T, Ishihara S, Yashima K, et al. Bleeding risk related to upper gastrointestinal endoscopic biopsy in patients receiving antithrombotic therapy: A multicenter prospective observational study. Curr Ther Res Clin Exp. 2017;84:32–6.
Ono S, Fujishiro M, Hirano K, et al. Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. J Gastroenterol. 2009;44(12):1185–9.
Ara N, Iijima K, Maejima R, et al. Prospective analysis of risk for bleeding after endoscopic biopsy without cessation of antithrombotics in Japan. Dig Endosc. 2015;27(4):458–64.
Kishida Y, Hotta K, Imai K, et al. Risk analysis of colorectal post-polypectomy bleeding due to antithrombotic agent. Digestion. Karger Publishers; 2018;4:1–9.
Lin D, Soetikno RM, McQuaid K, et al. Risk factors for postpolypectomy bleeding in patients receiving anticoagulation or antiplatelet medications. Gastrointest Endosc. 2018;87(4):1106–13.
Ben-Menachem T, Decker G, Early D, et al. Adverse events of upper GI endoscopy. Gastrointest Endosc. 2012;76(4):707–18.
Anderloni A, Jovani M, Hassan C, et al. Advances, problems, and complications of polypectomy. Clin Exp Gastroenterol. Dove Press;2014;7:285–96.
Ferlitsch M, Moss A, Hassan C, et al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. © Georg Thieme Verlag KG; 2017;49(03):270–97.
Kapetanos D, Beltsis A, Chatzimavroudis G, et al. Postpolypectomy bleeding: Incidence, risk factors, prevention, and management. Surg Laparosc Endosc Percutan Tech. 2012;22(2):102–7.
Yanagisawa N, Nagata N, Watanabe K, et al. Post-polypectomy bleeding and thromboembolism risks associated with warfarin vs direct oral anticoagulants. World J Gastroenterol. Baishideng Publishing Group Inc. 2018;24(14):1540–9.
Grossman EB, Maranino AN, Zamora DC, et al. Antiplatelet medications increase the risk of post-polypectomy bleeding. Gastrointest Endosc. 2010;71(5):AB138.
Wang J, Zhang X-H, Ge J, et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal tumors: a meta-analysis. World J Gastroenterol. 2014;20(25):8282–7.
Terasaki M, Tanaka S, Oka S, et al. Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm. J Gastroenterol Hepatol. 2012;27(4):734–40.
Nanda KS, Bourke MJ. Endoscopic mucosal resection and complications. Tech Gastrointest Endosc. 2013;15(2):88–95.
Katsinelos P, Lazaraki G, Chatzimavroudis G, et al. Risk factors for therapeutic ERCP-related complications: an analysis of 2,715 cases performed by a single endoscopist. Ann Gastroenterol. 2014;27(1):65–72.
Jang DK, Lee SH. The bleeding risk after endoscopic ultrasound-guided fine needle aspiration in patients taking antithrombotic agents is not negligible. Gut Liver. 2018;12(3):225–6.
Akintoye E, Kumar N, Aihara H, et al. Colorectal endoscopic submucosal dissection: a systematic review and meta-analysis. Endosc Int open. 2016;4(10):E1030–44.
Daoud DC, Suter N, Durand M, et al. Comparing outcomes for endoscopic submucosal dissection between Eastern and Western countries: A systematic review and meta-analysis. World J Gastroenterol. Baishideng Publishing Group Inc; 2018;24(23):2518–36.
Koh R, Hirasawa K, Yahara S, et al. Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms. Gastrointest Endosc. 2013;78(3):476–83.
Tsuji Y, Ohata K, Ito T, et al. Risk factors for bleeding after endoscopic submucosal dissection for gastric lesions. World J Gastroenterol. 2010;16(23):2913–7.
Matsumura T, Arai M, Maruoka D, et al. Risk factors for early and delayed post-operative bleeding after endoscopic submucosal dissection of gastric neoplasms, including patients with continued use of antithrombotic agents. BMC Gastroenterol. 2014;14(1):172.
Akintoye E, Obaitan I, Muthusamy A, et al. Endoscopic submucosal dissection of gastric tumors: A systematic review and meta-analysis. World J Gastrointest Endosc. 2016;8(15):517–32.
Goto O, Fujishiro M, Oda I, et al. A multicenter survey of the management after gastric endoscopic submucosal dissection related to postoperative bleeding. Dig Dis Sci. 2012;57(2):435–9.
Chung I-K, Lee JH, Lee S-H, et al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. Gastrointest Endosc. 2009;69(7):1228–35.
Mannen K, Tsunada S, Hara M, et al. Risk factors for complications of endoscopic submucosal dissection in gastric tumors: analysis of 478 lesions. J Gastroenterol. 2010;45(1):30–6.
Okada K, Yamamoto Y, Kasuga A, et al. Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm. Surg Endosc. 2011;25(1):98–107.
Higashiyama M, Oka S, Tanaka S, et al. Risk factors for bleeding after endoscopic submucosal dissection of gastric epithelial neoplasm. Dig Endosc. 2011;23(4):290–5.
Toyokawa T, Inaba T, Omote S, et al. Risk factors for perforation and delayed bleeding associated with endoscopic submucosal dissection for early gastric neoplasms: Analysis of 1123 lesions. J Gastroenterol Hepatol. 2012;27(5):907–12.
Lim JH, Kim SG, Kim JW, et al. Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms? Gastrointest Endosc. 2012;75(4):719–27.
Venkatachalapathy S, Evans G, Muller A. Endoscopy and the risk of venous thromboembolism: A case-control study. Endosc Int Open. 2014;2(01):E2–5.
Nagata N, Sakurai T, Moriyasu S, et al. Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding. PLoS One. 2017;12(9):e0183423.
Chai-Adisaksopha C, Hillis C, Monreal M, et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. Thromb Haemost. 2015;114(10):819–25.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
